Is safety infliximab during pregnancy in patients with inflammatory bowel disease?

Revista Espanola de Enfermedades Digestivas

Volumn 104, Issue 2, 2012, Pages 59-64

  Argüelles Arias, Federico ^a   Castro Laria, Luisa ^a   Barreiro de Acosta, Manuel ^b   García Sánchez, Ma Valle ^c   Guerrero Jiménez, Pedro ^d   Gómez García, Ma Rosa ^e   Cordero Ruiz, Patricia ^a   Iglesias Flores, Eva ^c   Gómez Camacho, Federico ^c   Domínguez Muñoz, Enrique J ^b   Herrerías Gutiérrez, Juan Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Crohn's disease; Inflammatory bowel disease; Infliximab; Pregnancy; Ulcerative colitis

Indexed keywords

INFLIXIMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BODY WEIGHT; CESAREAN SECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DRUG SAFETY; ENTERITIS; FEMALE; GESTATIONAL AGE; HUMAN; LOW BIRTH WEIGHT; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREGNANCY; PREGNANT WOMAN; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; SPAIN; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; VAGINAL DELIVERY; BIRTH WEIGHT; EVALUATION; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIRTH WEIGHT; FEMALE; GESTATIONAL AGE; HUMANS; INFLAMMATORY BOWEL DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 84857737354     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082012000200003     Document Type: Article

References (26)

1. Garrido E, Van Domselaar M, Morales S, López-Sanromán A. Inflammatory bowel disease and pregnancy. Gastroenterol Hepatol 2010;33:517-29.
2. Raatikainen K, Mustonen J, Pajala MO, Heikkinen M, Heinonen S. The effects of pre- and post-pregnancy inflammatory bowel disease diagnosis on birth outcomes. Aliment Pharmacol Ther 2011;33: 333-9.
3. Molnár T, Farkas K, Nagy F, Lakatos PL, Miheller P, Nyári T, et al. Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a casecontrol study. Scand J Gastroenterol 2010;45:1302-6.
4. Food and Drug Administration. Regulations 1980;44:37434-7.
5. Vasiliauskas ED, Barry M, Dubinsky M. High serum levels of infliximab detected in the newborn of a mother receiving during pregnancy. Gastroenterology 2005;128:33.
6. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4:1255-8.
7. Zelinkova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ, Peppelenbosch MP, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011;33:1053-8.
8. Friedman S, Regueiro MD. Pregnancy and nursing in inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:265-73, xii.
9. Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010;16:881-95.
10. Lichtenstein G, Cohen R, Feagan B, Sandborn W, Salzberg B, Chen D. Safety of infliximab in Crohn's disease: Data from the 5000-patient TREAT registry. Gastroenterology 2004;126:A54.
11. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2385-92.
12. Joven BE, García-González AJ, Ruiz T, Moreno E, Cebrián L, Valero M. Pregnancy in women receiving anti-TNF therapy. Experience in Spain. Arthritis Rheum 2005;9(Supl.):S349.
13. Hyrich KL, Symmons DP, Watson KD, Silman AJ. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum 2006;54: 2701-2.
14. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, et al. DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005;21:733-8.
15. Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008;14:3085-7.
16. Burt MJ, Frizelle FA, Barbezat GO. Pregnancy and exposure to infliximab (anti-tumor necrosis factor-alpha monoclonal antibody). J Gastroenterol Hepatol 2003;18:465-6.
17. Puig L, Barco D, Alomar A. Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology 2010;220:71-6.
18. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009;36:635-41.
19. Koren G, Inoue M. Do tumor necrosis factor inhibitors cause malformations in humans? J Rheumatol 2009;36:465-6.
20. Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011;17:1846-54.
21. Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium, BSR Biologics Register. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:823-6.
22. Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis 2008;14:1736-50.
23. Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009;43:613-6.
24. Mahadevan U, Kane S. American Gastroenterological Association Institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006;131:283-311.
25. Nørgård B, Hundborg HH, Jacobsen BA, Nielsen GL, Fonager K. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 2007;102:1947-54.
26. Molnár T, Farkas K, Nagy F, Lakatos PL, Miheller P, Nyári T, et al. Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a casecontrol study. Scand J Gastroenterol 2010;45:1302-6.